Constitutively active Ras proteins, their regulatory components, and overexpressed tyrosine kinase receptors that activate Ras, are frequently associated with cell transformation in human tumors. This suggests that functional Ras antagonists may have anti-tumor activity. Studies in rodent ®broblasts have shown that S-trans, transfarnesylthiosalicylic acid (FTS) acts as a rather speci®c nontoxic Ras antagonist, dislodging Ras from its membrane anchorage domains and accelerating its degradation. FTS is not a farnesyltransferase inhibitor, and does not aect Ras maturation. Here we demonstrate that FTS also acts as a functional Ras antagonist in human pancreatic cell lines that express activated KRas (Panc-1 and MiaPaCa-2). In Panc-1 cells, FTS at a concentration of 25 ± 100 mM reduced the amount of Ras in a dose-dependent manner and interfered with serumdependent and epidermal growth factor-stimulated ERK activation, thus inhibiting both anchorage-dependent and anchorage-independent growth of Panc-1 cells in vitro. FTS also inhibited tumor growth in Panc-1 xenografted nude mice, apparently without systemic toxicity. Daily FTS treatment (5 mg/kg intraperitoneally) in mice with tumors (mean volume 0.07 cm 3 ) markedly decreased tumor growth (after treatment for 18 days, tumor volume had increased by only 23+30-fold in the FTStreated group and by 127+66-fold in controls). These ®ndings suggest that FTS represents a new class of functional Ras antagonists with potential therapeutic value.
Introduction
Ras proteins are members of a family of GTPases that are essential components of receptor-mediated signaling cascades which regulate cell growth and differentiation (Boguski and McCormick, 1993; Lange-Carter and Johnson, 1994; Cox and Der, 1997; Lowy and Wilumsen, 1993; Marshall, 1996) . They are also important components of signaling pathways that regulate cell death (Trent et al., 1996; Kinoshita et al., 1995) , cell shape and cell motility (Kundra et al., 1995; Khosravi-Far et al., 1998) . The ability of Ras proteins to serve as regulators of signal transduction is conferred on them by structural elements that promote reversible activation (exchange of GDP for GTP) and inactivation (GTP hydrolysis), and by additional structural elements that promote interaction with eector molecules and association with the cell membrane (Boguski and McCormick, 1993; Cox and Der, 1997; Marshall, 1996; Schezek et al., 1997) . Propagation of receptor signals to Ras eectors involves guanine nucleotide exchange factors that facilitate the exchange of GDP for GTP (McCormick, 1993; Fransworth et al., 1995; Bos, 1997) .
Termination of Ras eector interactions involves Ras
GTPase-activating proteins (Schezek et al., 1997) .
Human oncogenic Ras proteins, most frequently found as H-K-and N-Ras isoforms mutated at positions 12, 13 or 61, are insensitive to GTPaseactivating proteins (Barbacid, 1987; Bos, 1989 Bos, , 1995 . The constitutive activation of Ras, together with the activation or inactivation of other genes, contributes to uncontrolled cell growth, cell transformation, and the development of human cancer (Dhanasekaran et al., 1995; Fearon, 1997) . Moreover, many types of human tumors that do not harbor mutated ras genes may depend on Ras-regulated signal transduction pathways as well as on Ras activators and eectors. Overexpression or mutation of growth factor receptors, such as the epidermal growth factor (EGF) or platelet derived growth factor (PDGF) receptor, in combination with enhanced expression of their ligands, as well as abnormal tyrosine kinase function (Kolibaba and Druker, 1997; Huang et al., 1997; Smith et al., 1987) , have been found in a number of human malignancies. Mutated Ras proteins are detected in as many as 30% of human tumors (Barbacid, 1987; Bos, 1989 Bos, , 1995 , with the highest incidence in ductal tumors of the exocrine pancreas (Almoguera et al., 1988; Hubran et al., 1993; Rall et al., 1996) . Activation of the K-rasgene by point mutations is involved in pancreatic oncogenesis. Pellegata et al., 1994) .
These data highlight the potential bene®ts that Rasantagonists may provide in attempts to block the growth of human tumors. The ®rst group of functional Ras antagonists to be described where the farnesyltransferase inhibitors (FTIs) (James et al., 1993; Kohl et al., 1993 Kohl et al., , 1994 Lebowitz et al., 1997; Nagasu et al., 1995; Manne et al., 1995; Sun et al., 1995; Gibbs and Oli, 1997) . Although these inhibitors are not targeted directly towards Ras, they can block Ras functions because Ras farnesylation is essential for Ras membrane anchorage, Ras signaling, and Ras transforming activity (Casey et al., 1989; Hancock et al., 1989 Hancock et al., , 1991 . Several FTIs indeed inhibit anchoragedependent and -independent growth of Ras-transformed cells in vitro (Cox and Der, 1997) . Some of these inhibitors reduce tumor growth in animal models (Kohl et al., 1994; Sun et al., 1995) .
In spite of these encouraging results, studies using FTIs have uncovered some limitations in connection with their use as inhibitors of cell growth, and have pointed to the possibility that some of their growthinhibitory eects may not be related to inhibition of Ras farnesylation (Cox and Der, 1997) . A signi®cant limitation is that K-and N-Ras, the Ras isoforms most frequently found to be activated by point mutations in human tumors (Bos, 1989 (Bos, , 1995 Sepp-Lorenzino et al., 1995) , undergo geranylgeranylation in cells treated by FTIs (Rowell et al., 1997; Whyte et al., 1997) . Since KRas can indeed serve as a substrate for the enzyme geranylgeranyltransferase-I , and since activated geranylgeranylated K-Ras presents transforming activity Der, 1992, 1997) , these observations may explain why several human tumor cell lines that express activated K-Ras are resistant to FTIs. Taken together, these considerations point to the importance of the development of new approaches, independent of prenyltransferases, to aect Ras functions.
We previously proposed an approach to the manipulation of Ras proteins by using the synthetic S-prenyl derivatives of rigid carboxylic acid Marom et al., 1995) . We found that these compounds inhibit the growth of H-Ras-transformed cells in a dose-dependent manner, with distinctive structure-function relationships Aharonson et al., 1998) . The most potent inhibitor, S-transfarnesylthiosalicylic acid (FTS), inhibits the growth of H-Ras-transformed Marom et al., 1995; Aharonson et al., 1998) and K-Ras-transformed (unpublished data) rodent ®broblasts by its direct eect on membrane-anchored Ras, and not by inhibition of the enzyme farnesyltransferase . FTS appears to act as a rather speci®c Ras antagonist. It inhibits the growth of Ras-transformed and ErbB2-transformed fibroblasts, but not of v-Raf-transformed cells . Its mechanism of action is likely to be associated primarily with the dislodgment of the mature protein from membrane domains that interact with Ras (Siddiqui et al., 1998) and with the subsequent accelerated degradation of the dislodged Ras proteins . These eects of FTS are manifested by a decrease in the amount of cellular Ras accompanied by interruption of the Ras-dependent Raf-1-extracellular signal-regulated kinase (ERK) signaling cascade (Gana-Weisz et al., 1997) .
Based on our previous observations, we have proposed that FTS and several of its analogs may be useful growth inhibitors of human tumor cells that harbor activated ras genes or genes that encode Rasregulating proteins Haklai et al., 1998) . This suggestion was not tested thus far. Namely, it was not known whether FTS and its analogs can inhibit growth of human tumor cells and whether they can inhibit Ras-dependent transforming activity. In the present study we examined these possibilities by analysing the eects of FTS on human pancreatic tumor cell lines which, like human pancreatic tumor cells, carrying activating K-ras mutations (Berrozope et al., 1994) and are characterized by a relatively high expression of EGF receptors (Korc et al., 1986; Chen et al., 1990; Lemoine et al., 1992) . This is an important trial because of the high incidence of K-ras gene mutations in human pancreatic tumors (Barbacid, 1987; Bos, 1989 Bos, , 1995 . Furthermore, some human pancreatic cell lines (e.g. Panc-1) are resistant to FTIs (Sepp-Lorenzino et al., 1995) . We show here that FTS can inhibit the anchorage-dependent growth of Panc-1 and of MiaPaCa-2 cells that express activated K-Ras. FTS caused a dose-dependent decrease in the amount of Ras in Panc-1 cells, inhibited their basal and EGFstimulated ERK activity, and inhibited their anchorage-independent growth in soft agar. Finally, we demonstrate that FTS inhibits tumor growth in Panc-1-implanted nude mice.
Results
To determine whether FTS can aect Ras in human pancreatic tumor cells, we used Panc-1 cells that harbor an activated K-ras allele (Berrozpe et al., 1994) . The cells were grown for 24 h both in the absence and in the presence of FTS (5 ± 50 mM), and Ras proteins were then determined in the cell lysates by immunoblots/enhanced chemiluminescence (ECL) assays with pan-anti-Ras antibodies . As shown in Figure 1a , FTS caused a dose-dependent decrease in the total amount of Ras in Panc-1 cells. The maximal reduction in the amount of Ras (about 50%) and the concentrations at which FTS induced this eect (25 ± 50 mM) were similar to those recorded in rodent ®broblasts transformed by H-Ras (12V) Haklai et al., 1998) or by K-Ras (12V) (unpublished data). The FTS-induced decrease in the amount of Ras observed in H-Ras-transformed Rat-1 cells re¯ects the drug-induced dislodgment and accelerated degradation of Ras in these cells . We therefore examined whether FTS also facilitates the rate of Ras degradation in Panc-1 cells. The cells were labeled with 35 S-cysteine/methionine for 6 h then chased in the absence and in the presence of 25 mM FTS for various periods of time with unlabeled cysteine/methionine. Ras proteins were then immunoprecipitated from the cell lysates with Y13-259 anti Ras antibodies and separated by SDS ± PAGE .
35
S-Ras, determined by autoradiography, was then quanti®ed (see Materials and methods). Results of a typical experiment (shown in Figure 1b) indicate that FTS facilitated the rate of Ras degradation in Panc-1. The estimated half-lives of Ras were 412 h and 7 ± 8 h in the controls and in the FTS-treated cells respectively.
We next examined whether the eects of FTS on Ras are also manifested in the inhibition of the Rasdependent mitogen activated protein kinase (MAPK) ERK, which is required for cell growth and transformation (Seger et al., 1991; Cobb and Goldsmith, 1995) . Panc-1 cells were grown in the presence of Dulbecco's modi®ed Eagle medium (DMEM)/10% fetal calf serum (FCS) for 24 h with 5 ± 25 mM FTS. ERK1 and 2 were then immunoprecipitated from cell lysates, and their activity determined with myelin basic protein (MBP) or with MBP peptide S5 as a substrate. Results of a typical experiment (shown in Figure 2a ) indicate that FTS, in a dose-dependent manner, inhibited ERK activity of Panc-1 cells that were grown in 10% FCS. In a similar set of experiments, we examined the eects of FTS on EGF-stimulated ERK activity in Panc-1 cells. The cells were grown in 0.1% FCS in DMEM with and without FTS (5 ± 50 mM) and then stimulated with 30 ng/ml EGF. ERK activity was assayed in the cell lysates. The results of these experiments showed that FTS inhibits the EGFstimulated ERK activity in a dose-dependent manner (Figure 2b ). We noted that under the low serum conditions (0.1% FCS) employed in this set of experiments, FTS at concentrations higher than 75 mM was cytotoxic.
The results described above demonstrated that FTS at concentrations of 5 ± 50 mM can reduce the amount of Ras and inhibit Ras-dependent signaling in Panc-1 cells. To examine whether these eects are also manifested in the inhibition of Panc-1 cell growth, we examined the eects of FTS on the incorporation of [ 3 H]thymidine into DNA and on the anchoragedependent growth of the cells. As shown in Figure 3 , [ 3 H]thymidine incorporation into DNA in Panc-1 cells was inhibited by FTS (5 ± 25 mM), suggesting the inhibition of signaling for cell growth. The eects of FTS on the anchorage-dependent cell growth were then examined in cells that were grown (in 10% FCS/ DMEM) in the presence and in the absence of FTS (25 ± 100 mM), and the cells were counted after 5 days of growth. Initial results indicated that under these conditions FTS (up to 50 mM) did not cause cell death, as assessed by trypan blue staining. Cell treatment with 100 mM FTS resulted in a low degree of cytotoxicity (520% cell death). Photomicrographs of Panc-1 cells treated with FTS (25 ± 100 mM) (Figure 4 ) demonstrate that FTS caused a dose-dependent inhibition of cell proliferation. A typical dose ± response curve describing the eect of FTS on Panc-1 cell growth is shown in Figure 5a . The estimated IC 50 (concentration of FTS causing 50% inhibition of cell growth) was 35.2+3.2 mM (n=3). In addition to FTS we examined the eects of its 5-Cl and 5-F analogs, previously shown to inhibit the growth of H-Ras(V12)-trans- formed Rat-1 ®broblasts (Aharonson et al., 1998) . Both compounds were found to inhibit the growth of Panc-1 cells in a dose-dependent manner ( Figure 5b ). The estimated IC 50 values for 5-Cl-FTS and 5-F-FTS were 35+8.0 and 32+9.0 mM, respectively (Table 1) . We also examined the eects of N-acetyl-S-farnesyl-Lcysteine (AFC) and S-geranyl thiosalicyclic acid (GTS) on Panc-1 cell growth. These S-prenyl analogs which have no eect on the growth of H-Ras(12V)-transformed Rat-1 cells (Aharonson et al., 1998) also did not inhibit the growth of Panc-1 cells (Figure 5b ).
We then examined the ability of FTS to inhibit the growth of human pancreatic tumor cells other than Panc-1. For this set of experiments we used the MiaPaCa-2 cell line which, like Panc-1, harbors an activated K-ras allele. The results (Figure 5a , (Figure 5a ). Growth of NIH3T3 Cell growth was estimated by direct counting of cells grown for 5 days in the absence and in the presence of various drug concentrations, as described in Figure 4 . IC 50 values represent drug concentrations that yield 50% inhibition of cell growth (mean+s.d., n=3). Value 4100 mM means that there was no eect on cell growth cells over expressing wt-Ras was also not inhibited by FTS (Table 1) . Clearly, then, the two human cell lines that express activated K-Ras (Panc-1 and MiaPaCa-2) are sensitive to FTS.
Next we examined the ability of FTS to inhibit the anchorage-independent growth of human Panc-1 cells in soft agar. The cells were seeded, with or without FTS (10 ± 100 mM), and the sizes and numbers of colonies were estimated on day 17. As shown in Figure  6 , Panc-1 cells formed relatively large colonies in soft agar, and FTS induced a dose-dependent decrease in their size. A quantitative analysis of the data is presented in Table 2 . As shown, FTS caused complete disappearance of colonies larger than 200 mm, a decrease in the number of colonies 100 ± 200 mm in size (50% decrease at 25 mM FTS), and a decrease in the number of colonies smaller than 100 mm (50% decrease at 100 mM FTS). Under these conditions, FTS inhibited cell growth with no apparent cytotoxic eect. Taken together, these results suggest that FTS can suppress the transformation of Panc-1 cells.
To evaluate the anti-tumor ecacy of FTS, we used a nude mouse model with human Panc-1 cells implanted subcutaneously into the right¯ank area. In the ®rst experiment, cell implantation and FTS treatment (5 mg/kg intraperitoneally (i.p.) daily) were begun on the same day. After 21 days the tumors were removed from the animals and weighed. The mean tumor weight was 5.18+1.01 g in the control mice and 1.16+0.77 g in the FTS-treated mice, indicating that FTS caused signi®cant inhibition of Panc-1 tumor growth (78% inhibition, P50.05, t-test). In a second set of experiments we examined the eects of FTS on tumor growth in mice that had already developed Panc-1 tumors. Following cell implantation the mice were randomly separated into control (n=10) and FTS-treated (n=8) groups. FTS treatment (5.0 mg/ kg i.p. daily) was started 14 days after tumor implantation, by which time the tumors were 0.03 ± 0.12 cm 3 (mean, 0.07 cm 3 ) in size. Treatment was continued for 18 days. As shown in Figure 7 , FTS caused marked inhibition of Panc-1 tumor growth, which was signi®cant from day 11 of the treatment. During these 18 days the average tumor volume in the control group increased by 127+67-fold, compared to an increase of only 23+30-fold in the FTS-treated group. There was no evidence of weight loss, gross toxicity or any abnormal features in the FTS-treated animals.
In separate sets of experiments, we estimated the LD 50 (lethal dose for 50% of the mice) by a single i.p. administration of FTS over a concentration range of Pnac-1 cells were grown on soft agar with or without the indicated concentrations of FTS, as described in Figure 5 . The sizes and numbers of colonies of duplicate wells were estimated on day 17, as described in Materials Panc-1 cells (subcutaneously above the right femoral joint). After 14 days they were separated into two groups, an experimental group that received 5 mg/kg of FTS (i.p. daily) and a control group that received the vehicle (i.p. daily). Tumor volume was estimated on day zero of treatment and subsequently on the days indicated. Data are presented as the fold increase in tumor volume (mean+s.d.; n=8 in FTS-treated mice and n=10 in control mice; P50.05 from day 11 on) 2.5 ± 200 mg/kg. The estimated LD 50 was 75 ± 100 mg/ kg. Toxicological experiments were carried out for a further 2 weeks in mice receiving daily i.p. injections of 5 mg/kg FTS. Blood tests were performed during this period, and the animals were then sacri®ced and their organs (lung, heart, liver, spleen, kidney, thymus, testis and brain) weighed. No eect of FTS treatment on animal or tissue weight was observed. Similarly, FTS treatment did not aect blood counts (erythrocytes, leukocytes or platelets), creatinine, liver enzymes or creatine kinase (all isoforms). We conclude that there are no adverse toxic eects at the eective FTS dosage for inhibition of tumor growth in the nude mouse model.
Discussion
Previous studies have shown that FTS can act as a selective Ras antagonist in rodent ®broblasts Marom et al., 1995; Aharonson et al., 1998; Haklai et al., 1998) . Its mechanism of action appears to be associated primarily with the dislodgment of mature Ras from anchorage domains in the cell membrane and the facilitation of Ras degradation . The eects of FTS in HRas(12V)-transformed or K-Ras(12V)-transformed (unpublished observations) rodent ®broblasts are manifested in a decrease in the total amount of cellular Ras. It is important to note that FTS does not inhibit Ras farnesylation or Ras methylation at the eective concentration range . Also, FTS has no eect on the amount of the N-myristylated (non-farnesylated) Ras isoform, or on the amount of the prenylated Gbg subunits of heterotrimeric Gproteins in Rat-1 cells . These data suggest that FTS and some of its analogs Aharonson et al., 1998) act as functional and speci®c Ras antagonists and may therefore serve as a new class of compounds with clinical potential. This concept is supported by the results of the present study, which demonstrate that FTS can reduce the amount of Ras in a cell line derived from a malignant human pancreatic tumor that harbors an activated K-ras (12D) gene, namely the Panc-1 cell line (Berrozpe et al., 1994) . The FTS-induced decrease in Ras appears to be manifested in reduced ERK activity, inhibition of DNA synthesis, and inhibition of both anchorage-dependent and anchorage-independent growth of Panc-1 cells. Signi®cantly, FTS at the relatively low dose of 5 mg/kg eectively reduced tumor growth in Panc-1 xenografted nude mice that had already developed tumors having an average size of 0.07 cm 3 . In comparison to the in vivo eective doses (20 ± 100 mg/kg) of some potent farnesyltransferase inhibitors (Kohl et al., 1994; Sun et al., 1995) , FTS appears to be among the most potent functional Ras antagonists that have been described to date. At the eective dosage FTS did not cause adverse toxic eects in nude mice. This, and the relatively high LD 50 (75 ± 100 mg/kg), suggest that FTS exhibits a remarkable therapeutic ratio in these animals. Interestingly, although their mechanisms of action are dierent, farnesyltransferase inhibitors also appear to be very safe compounds (Cox and Der, 1997; Sepp-Lorenzino, 1995; Meimbrook and Oli, 1998) . These compounds, however, inhibit the processing of Ras, thereby preventing its association with the cell membrane (James et al., 1993; Kohl et al., 1993 Kohl et al., , 1994 Lebowitz et al., 1997; Nagasu et al., 1995; Manne et al., 1995; Sun et al., 1995) .
The results described here indicate that the eects of FTS on Ras, on ERK and on cell growth are not limited to rodent ®broblasts. In Panc-1 cells (Figure  1a) , as in Rat-1 cells expressing activated H-Ras Haklai et al., 1998) or in NIH-3T3 cells expressing activated K-Ras (unpublished data), FTS caused a reduction in the amount of Ras. We have previously shown that inhibition of Ras processing by lovastatin in H-Ras(12V)-transformed Rat-1 cells caused the accumulation of unprocessed (e.g. a slowly migrating) Ras (Gutierrez et al., 1989) , whereas under the identical conditions, FTS (which caused a reduction in the amount of Ras protein) did not induce unprocessed Ras to accumulate . Similarly, in this study we did not ®nd slowly migrating Ras isoforms in Panc-1 cells that were treated with FTS, although the total amount of Ras protein was signi®cantly reduced (Figure 1a) . It thus appears that in human Panc-1 cells, as in rodent ®broblasts, FTS accelerates the degradation of mature Ras proteins. This emphasizes the substantial dierence between the mechanisms of action of the FTIs and FTS. While the former group deplete membrane Ras by inhibition of its maturation, the latter depletes cellular Ras by accelerating its degradation.
The precise mode of FTS-induced degradation of Ras in ®broblasts or in Panc-1 cells is not yet known. We do know, however, that in the case of Rat-1 cells, FTS dislodges Ras from putative Ras-anchorage sites in the cell membrane . It thus appears that once Ras is released from such sites as a result of the action of FTS, it becomes susceptible to degradation. It should be pointed out that Ras proteins appear to be localized in speci®c membrane domains such as caveolae or related domains enriched in glycosphingolipids and cholesterol (Song et al., 1996; Mineo et al., 1996; Simons and Ikonen, 1997) . Both wild-type (wt) H-Ras and activated H-Ras were found to be localized in such membrane domains, although ®broblasts transformed by activated H-Ras appear to have lost their caveolae (Koleske et al., 1995) . FTS may exert its action by interfering with the interaction of Ras with speci®c lipids and proteins present in caveolae or in analogous membrane domains (Lisanti et al., 1994; Simons and Ikonen, 1997) , or by interfering with the interaction of Ras with a recently described Ras-binding protein (Siddiqui et al., 1998) . Distinction between these and other mechanisms should become possible given the progress in our understanding of the mode of interactions of Ras and of other proteins with membrane domains. However, the knowledge that speci®c localization of Ras in the cell membrane requires its farnesylation (Hancock et al., 1991; Cox and Der, 1997) , coupled with the demonstrated lack of FTS eects on N-myristylated (non-farnesylated) Ras localized nonspeci®cally in the cell membrane, suggest that FTS interferes with membrane anchorage sites that recognize the S-farnesylcysteine moiety of Ras. This notion is supported by the observed eects of FTS on dierent types of Ras proteins including those expressed by Panc-1 cells, since all Ras proteins share the requirement of farnesylation for membrane anchorage (Hancock et al., 1991; Cox and Der, 1997) . Further support for a rather speci®c eect of FTS on membrane domains that associate Ras comes from the observed distinctive structural requirements of Sprenyl analogs for their anti-Ras activity in rodent ®broblasts. More speci®cally, we know that among such analogs, the 5-Cl and 5-F derivatives of FTS, but not AFC and GTS, are potent antagonists of Ras (Aharonson et al., 1998) . The results of the present study show similar structure-function relationships among these analogs for the inhibition of Panc-1 cell growth.
Additional support for the concept that FTS interferes with Ras-membrane interaction comes from our recent biophysical experiments in cells expressing the green¯uorescent protein (GFP) fused to K-Ras 4B (12V) (unpublished observations). We found that GFP-K-Ras 4B (12V) undergoes fast lateral diusion in the cell membrane and that FTS (but not AFC or GTS) induced a rapid increase in the lateral mobility of GFP-K-Ras 4B (12V) which occurred prior to the dislodgment of the protein into the cytosol. This eect re¯ects the drug-induced release of some constraints on the mobility of GFP-K-Ras 4B (12V), consistent with a potential mechanism whereby FTS disrupts the interactions of Ras with lipids and/or with Ras interacting proteins.
An important consequence of the eects of FTS on various Ras isoforms including wt and activated Ras is the inhibition of basal and growth factor-stimulated ERK activity in ®broblasts (Gana-Weisz et al., 1997) and in Panc-1 cells ( Figure  2 ). This is noteworthy because ERK is required for Ras-dependent cell growth and cell transformation (Seger et al., 1991; Cobb and Goldsmith, 1995) . We found that FTS inhibited DNA synthesis in Panc-1 cells (Figure 3) , attenuated the anchorage-dependent growth of Panc-1 and MiaPaCa-2 cells (Figures 4 and  5 ) and inhibited the anchorage-independent growth of Panc-1 cells (Figure 6 ). The inhibition of EGFstimulated ERK activity by FTS in Panc-1 cells (Figure 2b ) suggests that FTS aects not only activated K-Ras but also wt Ras isoforms. This is important because Panc-1 cells, as well as many other types of human tumor cells, overexpress tyrosine kinase receptors such as those belonging to the ErbB family of receptors including ErbB1 (EGF receptors) and ErbB2 (Salomon et al., 1995; Sepp-Lorenzino et al., 1995) . Moreover, the highly ecient FTS-induced blockage of EGF-stimulated ERK activity in Panc-1 cells (Figure 2b ) and in untransformed Rat-1 cells (Gana-Weisz et al., 1997) , together with the observed inhibition of the mitogenic eects of EGF and ®broblast growth factor (FGF) in ®broblasts , suggests that the sensitivity of transformed cells to FTS may not be dependent on their Ras-mutation status alone. We have previously shown that the growth of NIH3T3 cells transformed by ErbB2 is indeed inhibited by 5 ± 25 mM FTS , and we recently found that FTS inhibits the growth of human melanoma cells that do not express activated Ras (unpublished data). In this connection it is interesting to note that previous studies have shown a lack of correlation between Ras-mutation status and sensitivity to FTIs (Sepp-Lorenzino et al., 1995; Cox and Der, 1997) . This similarity between sensitivity to FTS and to FTIs is of course not surprising, as both of these functional Ras antagonists aect Ras whether or not it is in its activated state.
It is more dicult to explain why the growth of untransformed cells is not inhibited by FTS see Figure 3 ) or by FTIs (James et al., 1993; Kohl et al., 1993) . A likely explanation for the resistance of untransformed cells to FTIs is the alternative prenylation of N-or K-Ras isoforms by the enzyme geranylgeranyltransferase I Rowell et al., 1997; Whyte et al., 1997) . This does not however, seem to be the case with untransformed cells treated with FTS, because FTS appears to aect all Ras isoforms. We think that a combination of at least two factors may contribute to the resistance of these cells to FTS. One factor is associated with the somewhat lower sensitivity to FTS (2 ± 3-fold) of wt Ras over activated Ras . This lower sensitivity may re¯ect dierent membrane domains with which wt Ras and activated Ras would interact. The other factor is associated with alternative signaling pathways that untransformed cells may use; perhaps these cells are less dependent on Ras than cells which express a constitutively activated Ras protein.
The apparently unexpected phenomenon of alternative prenylation of N-and K-Ras proteins (Rowell et al., 1997; Whyte et al., 1997) raises important practical and mechanistic questions concerning the use and mode of action of FTIs. These questions arise in particular because some human tumor cell lines that express activated K-or N-Ras are insensitive to FTIs while others are sensitive (Sepp-Lorenzino et al., 1995) . This observation and other data led to the suggestion that FTIs may exert their growth-inhibitory eects on tumor cells that express activated K-or N-Ras by the inhibition of as yet unidenti®ed farnesylated protein(s) important for Ras-dependent cell transformation (Cox and Der, 1997) .
We also cannot rule out the possibility that, like FTI's, FTS may interfere with the action of other prenylated proteins such as proteins of the Rac/Rho family of GTPases that are associated with the control of actin cytoskeleton, cell growth and cell transformation (Symons, 1996; Rodriguez-Viciana et al., 1997; Hall 1998) . In this regard, preliminary results in our laboratory showed that FTS induces alteration in actin cytoskeleton in H-Ras ± transformed Rat-1 cells. These alterations can be a re¯ection of the direct eects of FTS on Ras but may also be due to a change in Rac/ Rho functions. Additional experiments are required to distinguish between these possibilities.
Our ®ndings on the FTS-induced growth inhibition of Panc-1 or MiaPaCa-2 cells that express activated KRas are of particular interest. First, FTS appears to be eective in a human cell line that has proved resistant to FTIs, namely Panc-1 (Sepp-Lorenzino et al., 1995) . Second, we have previously suggested that the combined use of FTS and FTIs may result in a synergistic growth-inhibitory eect, as a consequence of the dierent mechanisms of action of these inhibitors . The present work adds strength to this suggestion. Importantly, even in cell lines that are sensitive to FTIs and express activated K-or N-Ras these inhibitors are expected to aect a target`X' (Cox and Der, 1997) , and not the activated Ras proteins, whereas FTS is expected to accelerate the degradation of activated Ras proteins. This possibility of a combined use of FTS and FTIs must await experimental data on the eects of FTS on geranylgeranylated K-and N-Ras isoforms that are expected to be formed in cells treated with FTIs.
Finally, it is worth reiterating that the anti-tumor eects of FTS may not be limited to tumors that harbor activated Ras genes. In a related study, we found that FTS can inhibit tumor growth in SCID mice implanted with human melanoma cell lines that do not express activated Ras (unpublished observations). Moreover, because FTS also blocks the mitogenic eect of EGF and FGF in Rat-1 fibroblasts and, as shown here, it blocks EGF-induced ERK activity in Panc-1 cells, it is possible that in addition to its eect on tumor cells that express activated Ras, FTS may also aect Ras-dependent processes that support tumor growth (e.g. angiogenesis). We suggest that the use of FTS as a non-cytotoxic anti-tumor drug may be advantagenous, particularly for those tumors that prove resistant to farnesyltransferase inhibitors or to other anti-tumor drugs. [g- 32 P]ATP (3000 Ci/mmol) was purchased from Amersham, [
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Materials
3 H]thymidine (6.7 Ci/mmol) from Du-Pont NewEngland Nuclear, anti-Ras antibodies (pan-Ras Ab) from Oncogene Research Products, anti-ERK2 antibodies from Santa-Cruz, and myelin basic protein (MBP) and protein A sepharose from Sigma. MBP peptide S5 was from BIOMOL, protein A agarose and EGF from Boehringer Mannheim, and Noble agar from Difco.
FTS, 5-¯uoro-FTS (5-F-FTS), 5-chloro-FTS (5-Cl-FTS), S-geranylthiosalicylic acid (GTS), and N-acetyl-S-Farnesyl-Lcysteine (AFC) were prepared as described previously . The purity of the compounds, as assessed by TLC, H 1 -NMR and mass spectrometry, was 495%. Compounds for each set of experiments were prepared in chloroform (0.1 M stock solutions) and kept at 7708C. The chloroform was removed from the stock solution by a stream of nitrogen prior to use, and FTS or its analogs were then dissolved either in DMSO (in vitro experiments) or in ethanol (in vivo experiments). The FTS/ DMSO solutions were diluted with DMEM/10% FCS to yield a 1006 drug-stock solution containing 10% DMSO. A portion of this solution was applied to the cells at a dilution of 1:100. The FTS/ethanol solution was alkalinized by the addition of 1N NaOH, then diluted with phosphate-buered saline (PBS) to obtain a solution of 1.0 mg FTS/ml (pH 8.0, 0.5% ethanol). This solution (100 ± 150 ml per mouse) was used in the in vivo experiments.
Cell culture procedures
The human pancreatic cell lines Panc-1 and MiaPaca-2 were obtained from the American Tissue Culture Collection. NIH3T3 cells were transfected with pZIP H-Ras (wt) (a gift from Adrienne Cox) and stable transfectants were selected in a medium containing G418 (800 mg/ml). Cells were routinely grown in DMEM/10% FCS at 378C in a humidi®ed atmosphere of 95% air/5% CO 2 . To estimate the eects of FTS and its analogs on the anchoragedependent cell growth, cells were plated at a density of 2610 3 cells per well in 24-well plates, to which either 0.1% DMSO (control) or the test concentration of the analog was added after 24 h. Treated cells were grown for 5 days, detached and counted. All assays were performed in triplicate.
Soft agar assays
Cells were seeded at a density of 1610 4 cells per well in 6-well plates. The cells (in DMEM/10% FCS) were mixed with 0.5 ml of 0.33% Noble agar. The mixture was poured onto a layer of 1.5 ml 0.5% Noble agar in DMEM/10% FCS. The upper layer of agar was covered with 250 ml of medium. All agar layers contained either 0.1% DMSO (control) or FTS dissolved in 0.1% DMSO. Assays were performed in duplicate. The numbers and sizes of colonies were estimated on day 17, using a light microscope with an image analyser program. Three visual ®elds per well were analysed.
Tumor implantation
Nude CK 1 -Nu mice (6 weeks old) were housed in barrier facilities on a 12 h light/dark cycle. Food and water were supplied ad libitum. On day zero, 2.5610 6 Panc-1 cells in 0.1 ml of PBS were implanted subcutaneously just above the right femoral joint. On day 14 the mice were randomly separated into FTS-treated and control groups. The experimental animals received daily i.p. injections of 100 ± 150 ml of FTS (5 mg/kg) while the controls received daily i.p. injections of the vehicle solution (100 ± 150 ml). 
Determination of Ras
Panc-1 cells were plated at a density of 4610 6 cells/10 cm dish. After 12 h, the cells were treated for 24 h with FTS (5 ± 50 mM). The amount of Ras in the total cell lysates was then determined as described Haklai et al., 1998) . Brie¯y, 25 mg of total cellular proteins were separated by 12.5% sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS ± PAGE) and blotted onto nitrocellulose paper. Immunoblotting with pan-Ras antibodies (1:2000) and ECL assays were then performed as described .
The rate of Ras degradation was determined by pulsechase experiments. Panc-1 cells were plated at a density of 3610 6 cells/10-cm dish in DMEM/10% fetal calf serum (FCS). One day after plating the cells were starved of serum and methionine and pulsed with 200 mCi/ml 35 S-cysteine/ methionine (1000 Ci/mmol, DuPont NEN) for 6 h. The cells were then chased by removal of the medium and addition of fresh medium (containing methionine and 25 mM FTS) or 0.1% DMSO (control). The cells were detached at zero time or after 1, 6 or 12 h, and Ras proteins were then immunoprecipitated with Y13-259 anti-Ras antibodies and separated by SDS ± PAGE . [
35 S]cysteineRas, determined by autoradiography, was quanti®ed using TINA 2.0 software by Test (Staubenhardt, Germany).
MARK assay
The eects of FTS on MAPK activity in Panc-1 cells grown in 10% FCS were determined as described (GanaWeisz et al., 1997) . Brie¯y, Panc-1 cells were plated at a density of 1610 6 cells/10 cm dish in DMEM/20% FCS. After 24 h the cells received either FTS (5 ± 50 mM) or 0.1% DMSO (control) in the medium for a further 24 h. ERK activity was then assayed in the cell lysates, as follows: To each dish was added 1 ml of ERK lysis buer (50 mM b-glycerophosphate, 1.5 mM EGTA, 2 mM sodium orthovanadate, 1 mM dithiothreitol, 2 mg/ml leupeptin, 2 mg/ml aprotinin, 1 mM benzamidine and 1% NP-40), and the dishes were kept on ice for 10 min. The cell lysates were cleared by centrifugation and samples (500 mg protein) were then incubated with 5 ml of anti ERK-2 Ab and 30 ml of protein A-Sepharose beads. The immunoprecipitated ERK was then incubated for 30 min at 378C with kinase buers containing 30 mM Tris-HCl pH 8.0, 20 mM MnCl 2 , 2 mM MgCl 2 , 15 mg MBP, 10 mM ATP, and 5 mCi [g-32 P]ATP, 3000 Ci/mmol. The reaction was stopped by the the addition of 6 ml of 66Laemmli sample buer and heating for 5 min at 958C. Following a short spin, the supernatant was collected and the proteins separated by SDS ± PAGE (15% acrylamide) on mini-gels. Phosphorylated MBP was visualized by autoradiography of the dried gels on X-ray ®lms and quanti®ed by densitometric analysis.
The eects of FTS on EGF-stimulated ERK activity were determined as follows: Panc-1 cells were cultured in 10-cm culture dishes in DMEM/10% FCS until con¯uence was reached. Con¯uent cells were serum-starved for 17 h in DMEM/0.1% FCS plus the test concentrations of FTS or DMEM/0.1% FCS and 0.1% DMSO (control). The cells were then stimulated with 30 ng/ml EGF for 5 min, washed twice with ice-cold calcium-and magnesium-free PBS, and lysed in 500 ml of ice-cold RIPA buer per 10-cm dish (RIPA: 50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 0.1% SDS, 0.5% sodium-deoxycholate, 1% Triton X-100, 10 mM sodium pyrophosphate, 25 mM sodium b-glycerophosphate, 2 mM sodium vanadate, 1 mM leupeptin, 2.1 mg/ml aprotinin). After homogenization in a Dounce glass-homogenizer, nuclei and cell debris were removed by centrifugation for 15 min at 20 000 g at 48C. One milligram protein of the total cell lysate was used for MAPK immunoprecipitation with anti-ERK2 antibody. Following precoupling of 3 ml of the antibody with 25 ml of protein A-agarose, immunoprecipitation was allowed to proceed for 2 h at 48C with constant agitation. The precipitates were then washed twice with 500 ml RIPA buer and twice with kinase buer (15 mM Tris-HCl, pH 7.2, 15 mM MgCl 2 , 1 mM DTT). The samples were standardized to 30 ml, one-third was used for immunoblot analysis and the remaining 20 ml were assayed for MAPK activity. MAPK immunoprecipitates (20 ml) were incubated with 3 ml of myelin basic peptide S5 (MBP S5, 10 mg/ml in 100 ml Tris-HCl, pH 7.4), 2 ml ATP (20 mM) and 2 mCi [g-32 P]ATP for 10 min at 378C. The complete reaction mixture was spotted onto P81 cation-exchange chromatography paper and allowed to dry at room temperature. After washing three times in 180 mM phosphoric acid and brief incubation in acetone, the bound radioactivity was quanti®ed in a g-counter. All assays were performed in duplicate. 3 H]thymidine into DNA was measured in 2% trichloroacetic acid precipitates, as described (GanaWeisz et al., 1997) .
